ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug avacopan under Long-Term safety review for vasculitis patients
Disease control Recruiting nowThis study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE4 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immune cell therapy takes on autoimmune diseases
Disease control Recruiting nowThis study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could CAR t cells tame vasculitis? early trial aims to find out
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CC-97540, a type of CAR T cell therapy, in 12 people with severe ANCA-associated vasculitis that has not responded to standard treatments. The therapy is designed to target and destroy certain immune cells that drive the di…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1, PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental CAR-T therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…
Matched conditions: ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC